Archford Capital Strategies LLC Buys 11,548 Shares of Johnson & Johnson $JNJ

Archford Capital Strategies LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 85.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,023 shares of the company’s stock after purchasing an additional 11,548 shares during the quarter. Archford Capital Strategies LLC’s holdings in Johnson & Johnson were worth $5,178,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in JNJ. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $26,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the third quarter worth $28,000. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson in the second quarter valued at $27,000. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Citigroup upped their price objective on Johnson & Johnson from $250.00 to $274.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Leerink Partners raised their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. Finally, Guggenheim lifted their target price on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong clinical and product momentum — RCT data presented at ACC and published in JACC and JNJ’s recent pace of approvals/med‑tech launches bolster revenue visibility and the company’s long‑term growth story. Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now
• Positive Sentiment: R&D partnership deal — a reported $500M agreement with Royalty Pharma to advance an experimental autoimmune antibody provides non‑dilutive funding and validates JNJ’s pipeline strategy. Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal
• Positive Sentiment: Defensive, dividend appeal — coverage pieces highlight JNJ as a reliable dividend aristocrat and a low‑volatility healthcare hold during market stress, supporting investor demand in uncertain markets. This Healthcare Stock Barely Flinches During Market Sell-Offs
• Neutral Sentiment: Analyst interest and trending status — outlets note JNJ is trending on investor platforms and some analysts expect another earnings beat given its history; this can amplify short‑term flows but isn’t a new fundamental change. Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Major-holder activity — reports show Bridgewater (Ray Dalio) trimmed its position; large-manager moves can influence flows but don’t necessarily reflect company fundamentals. Johnson & Johnson (JNJ): Billionaire Ray Dalio Trims Position
• Negative Sentiment: MedTech China headwinds — previews ahead of Q1 highlight strong cardiovascular and new‑product adoption but warn of slowing demand in China, which is a near‑term earnings risk for the MedTech segment and likely a key reason shares are under pressure. JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
• Negative Sentiment: Valuation/rotation concerns — after a large one‑year rally, some commentary asks whether returns are largely priced in; combined with periodic profit‑taking, this contributes to downward pressure. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 61% One-Year Surge?

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $242.93 on Friday. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The company has a market capitalization of $585.11 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 2.42 and a beta of 0.34. The company has a 50-day simple moving average of $239.41 and a 200 day simple moving average of $212.30. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.